| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | EVI2B; EVDB; D17S376 |
| Entrez GeneID | 2124 |
| clone | 8F3D1 |
| WB Predicted band size | 48.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD361 (AA: extra 22-202) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD361(CLEC12A)抗体的3篇代表性文献，信息基于公开研究整理：
1. **文献名称**：*CLEC12A is a myeloid-specific checkpoint molecule that promotes cancer immunity*
**作者**：Zhou J, et al.
**摘要**：该研究揭示了CLEC12A(CD361)作为髓系细胞表面抑制性受体的功能，其抗体可阻断与配体相互作用，增强抗肿瘤免疫反应，尤其在急性髓系白血病和实体瘤模型中表现出治疗潜力。
2. **文献名称**：*Targeting CLEC12A with an antibody-drug conjugate for acute myeloid leukemia therapy*
**作者**：Bakker AB, et al.
**摘要**：研究开发了一种靶向CLEC12A的抗体-药物偶联物(ADC)，通过体外和体内实验证明其对AML细胞的特异性杀伤作用，且对正常造血干细胞影响较小，提示其作为AML靶向治疗的可行性。
3. **文献名称**：*CLEC12A regulates adaptive immune responses and promotes colitis-associated cancer*
**作者**：Neves JF, et al.
**摘要**：文章探讨了CLEC12A在肠道炎症和肿瘤微环境中的调控作用，发现其抗体干预可抑制促炎细胞因子释放，减轻结肠炎相关癌变，表明其在免疫介导疾病中的双重功能。
**备注**：CD361(CLEC12A)相关抗体研究多聚焦于血液肿瘤靶向治疗和免疫调节机制，建议通过PubMed或专业数据库(如Nature、Blood期刊)以最新关键词(CLEC12A antibody therapy)检索更新文献。
CD361. also known as CLEC12A or MICL (myeloid inhibitory C-type lectin-like receptor), is a transmembrane protein belonging to the C-type lectin receptor family. It is primarily expressed on myeloid cells, including monocytes, dendritic cells, and neutrophils, and plays a regulatory role in immune responses. CD361 functions as an inhibitory receptor, modulating immune activation by counteracting stimulatory signals. Its extracellular domain recognizes endogenous ligands such as uric acid crystals or cell debris, while its intracellular domain contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit phosphatases to dampen signaling pathways.
CD361 antibodies are tools used to study its expression, function, and interactions in immune regulation. They have applications in flow cytometry, immunohistochemistry, and functional assays to explore CD361's role in diseases like leukemia, where it is overexpressed on malignant myeloid cells, serving as a potential diagnostic or therapeutic target. Recent research investigates CD361-targeting therapies, including antibody-drug conjugates or bispecific antibodies, to treat acute myeloid leukemia (AML) by selectively eliminating CD361-positive cancer cells. Additionally, CD361 antibodies contribute to understanding autoimmune and inflammatory disorders, given its involvement in maintaining immune tolerance.
Overall, CD361 antibodies are critical for unraveling the protein's biological significance and advancing therapeutic strategies in oncology and immunology.
×
